The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
Research progress on drugs in treatment of autosomal dominant polycystic kidney disease
Author(s): 
Pages: 1167-1171
Year: Issue:  9
Journal: World Phytomedicines

Keyword:  polycystic kidney diseasetherapeutic drugsresearch progresstolvaptan;
Abstract: Autosomal dominant polycystic kidney disease (ADPKD) is a hereditary renal cystic disease. For lack of specific clinical therapy, it focuses on relieving the symptoms. If ADPKD develops to end-stage renal failure, patients need to take replacement therapy, such as dialysis, kidney transplantation. Therefore, in order to provide a reference for carrying on further clinical trials and treatment for ADPKD, the latest domestic and foreign research reports are reviewed and summarized. So far, there are vasopressin V2 receptor (AVPV2R) antagonists tolvaptan, mammalian target of rapamycin inhibitors sirolimus and everolimus, somatostatin analogues octreotide, and statins lovastatin and pravastatin in clinical trials, in which AVPV2R antagonist tolvaptan has been approved for the first drug in the world to delay the progression of ADPKD in Japan. But because of the adverse reactions, tolvaptan has not yet been formally approved by FDA. Large-scale clinical trials and subsequent risk - benefit analysis need to be further studied.
Related Articles
No related articles found